Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster
Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the re...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2013-08, Vol.208 (4), p.559-563 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 563 |
|---|---|
| container_issue | 4 |
| container_start_page | 559 |
| container_title | The Journal of infectious diseases |
| container_volume | 208 |
| creator | Morrison, Vicki A. Oxman, Michael N. Levin, Myron J. Schmader, Kenneth E. Guatelli, John C. Betts, Robert F. Gelb, Larry D. Pachucki, Constance T. Keay, Susan K. Menzies, Barbara Griffin, Marie R. Kauffman, Carol A. Marques, Adriana R. Toney, John F. Simberkoff, Michael S. Serrao, Richard Arbeit, Robert D. Gnann, John W. Greenberg, Richard N. Holodniy, Mark Keitel, Wendy A. Yeh, Shingshing S. Davis, Larry E. Crawford, George E. Neuzil, Kathy M. Johnson, Gary R. Zhang, Jane H. Harbecke, Rith Chan, Ivan S. F. Keller, Paul M. Williams, Heather M. Boardman, Kathy D. Silber, Jeffrey L. Annunziato, Paula W. |
| description | Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). Methods. A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. Results. The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was |
| doi_str_mv | 10.1093/infdis/jit182 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>42580632</jstor_id><sourcerecordid>42580632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-cd550f2b6e6c5674145daedcd2df50c21db48402890f939d0decb13754dcd77c3</originalsourceid><addsrcrecordid>eNpVkTtvFDEUhS1ERJZASQlyEynNJH573CBFeRCkRBSQFDSW14_glXe8sWeI9t9jNMuKVLc43zn36h4APmB0ipGiZ3EILtazVRxxT16BBeZUdkJg-hosECKkw71Sh-BtrSuEEKNCvgGHhApKGRILcPfdBD9uYQ7wZ66jL_DBWBsHD-MAr5LzJW3huZvSWOF1Tik_x-ERXmY7rf0wegdvfNn4ujO_AwfBpOrf7-YRuL---nFx091--_L14vy2s0ySsbOOcxTIUnhhuZAMM-6Md9YRFziyBLsl6xkivUJBUeWQ83aJqeSsMVJaegQ-z7mbabluxnZKMUlvSlybstXZRP1SGeIv_Zh_ayqx6pVoASe7gJKfJl9HvY7V-pTM4PNUNRaMCMJFjxvazagtudbiw34NRvpvBXquQM8VNP7T_7ft6X8_b8DxDjDVmhSKGWyz7zkpcC-JatzHmVvVMZe9zgjvWwqhfwDP1Zxd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1642625681</pqid></control><display><type>article</type><title>Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Morrison, Vicki A. ; Oxman, Michael N. ; Levin, Myron J. ; Schmader, Kenneth E. ; Guatelli, John C. ; Betts, Robert F. ; Gelb, Larry D. ; Pachucki, Constance T. ; Keay, Susan K. ; Menzies, Barbara ; Griffin, Marie R. ; Kauffman, Carol A. ; Marques, Adriana R. ; Toney, John F. ; Simberkoff, Michael S. ; Serrao, Richard ; Arbeit, Robert D. ; Gnann, John W. ; Greenberg, Richard N. ; Holodniy, Mark ; Keitel, Wendy A. ; Yeh, Shingshing S. ; Davis, Larry E. ; Crawford, George E. ; Neuzil, Kathy M. ; Johnson, Gary R. ; Zhang, Jane H. ; Harbecke, Rith ; Chan, Ivan S. F. ; Keller, Paul M. ; Williams, Heather M. ; Boardman, Kathy D. ; Silber, Jeffrey L. ; Annunziato, Paula W.</creator><creatorcontrib>Morrison, Vicki A. ; Oxman, Michael N. ; Levin, Myron J. ; Schmader, Kenneth E. ; Guatelli, John C. ; Betts, Robert F. ; Gelb, Larry D. ; Pachucki, Constance T. ; Keay, Susan K. ; Menzies, Barbara ; Griffin, Marie R. ; Kauffman, Carol A. ; Marques, Adriana R. ; Toney, John F. ; Simberkoff, Michael S. ; Serrao, Richard ; Arbeit, Robert D. ; Gnann, John W. ; Greenberg, Richard N. ; Holodniy, Mark ; Keitel, Wendy A. ; Yeh, Shingshing S. ; Davis, Larry E. ; Crawford, George E. ; Neuzil, Kathy M. ; Johnson, Gary R. ; Zhang, Jane H. ; Harbecke, Rith ; Chan, Ivan S. F. ; Keller, Paul M. ; Williams, Heather M. ; Boardman, Kathy D. ; Silber, Jeffrey L. ; Annunziato, Paula W. ; Shingles Prevention Study Group ; for the Shingles Prevention Study Group</creatorcontrib><description>Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). Methods. A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. Results. The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was <5 years for approximately 80% of recipients. The proportion of vaccinated SPS placebo recipients with prior HZ who developed ≥1 SAE (0.95%) was not significantly different from that of vaccinated SPS placebo recipients with no prior history of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable. Conclusions. These results demonstrate that the general safety of zoster vaccine in older persons is not altered by a recent history of documented HZ, supporting the safety aspect of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendation to administer zoster vaccine to all persons ≥60 years of age with no contraindications, regardless of a prior history of HZ.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jit182</identifier><identifier>PMID: 23633406</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Age ; Aged ; Aged, 80 and over ; Applied microbiology ; Biological and medical sciences ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - pathology ; Female ; Fundamental and applied biological sciences. Psychology ; Health care industry ; Herpes zoster ; Herpes Zoster - immunology ; Herpes zoster vaccine ; Herpes Zoster Vaccine - administration & dosage ; Herpes Zoster Vaccine - adverse effects ; Human viral diseases ; Humans ; Infectious diseases ; Major and Brief Reports ; Male ; Medical practice ; Medical sciences ; Microbiology ; Middle Aged ; Older adults ; Placebos ; Preventive medicine ; Vaccination ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye ; VIRUSES</subject><ispartof>The Journal of infectious diseases, 2013-08, Vol.208 (4), p.559-563</ispartof><rights>Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>2014 INIST-CNRS</rights><rights>Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2013. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-cd550f2b6e6c5674145daedcd2df50c21db48402890f939d0decb13754dcd77c3</citedby><cites>FETCH-LOGICAL-c472t-cd550f2b6e6c5674145daedcd2df50c21db48402890f939d0decb13754dcd77c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/42580632$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/42580632$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27618729$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23633406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morrison, Vicki A.</creatorcontrib><creatorcontrib>Oxman, Michael N.</creatorcontrib><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Schmader, Kenneth E.</creatorcontrib><creatorcontrib>Guatelli, John C.</creatorcontrib><creatorcontrib>Betts, Robert F.</creatorcontrib><creatorcontrib>Gelb, Larry D.</creatorcontrib><creatorcontrib>Pachucki, Constance T.</creatorcontrib><creatorcontrib>Keay, Susan K.</creatorcontrib><creatorcontrib>Menzies, Barbara</creatorcontrib><creatorcontrib>Griffin, Marie R.</creatorcontrib><creatorcontrib>Kauffman, Carol A.</creatorcontrib><creatorcontrib>Marques, Adriana R.</creatorcontrib><creatorcontrib>Toney, John F.</creatorcontrib><creatorcontrib>Simberkoff, Michael S.</creatorcontrib><creatorcontrib>Serrao, Richard</creatorcontrib><creatorcontrib>Arbeit, Robert D.</creatorcontrib><creatorcontrib>Gnann, John W.</creatorcontrib><creatorcontrib>Greenberg, Richard N.</creatorcontrib><creatorcontrib>Holodniy, Mark</creatorcontrib><creatorcontrib>Keitel, Wendy A.</creatorcontrib><creatorcontrib>Yeh, Shingshing S.</creatorcontrib><creatorcontrib>Davis, Larry E.</creatorcontrib><creatorcontrib>Crawford, George E.</creatorcontrib><creatorcontrib>Neuzil, Kathy M.</creatorcontrib><creatorcontrib>Johnson, Gary R.</creatorcontrib><creatorcontrib>Zhang, Jane H.</creatorcontrib><creatorcontrib>Harbecke, Rith</creatorcontrib><creatorcontrib>Chan, Ivan S. F.</creatorcontrib><creatorcontrib>Keller, Paul M.</creatorcontrib><creatorcontrib>Williams, Heather M.</creatorcontrib><creatorcontrib>Boardman, Kathy D.</creatorcontrib><creatorcontrib>Silber, Jeffrey L.</creatorcontrib><creatorcontrib>Annunziato, Paula W.</creatorcontrib><creatorcontrib>Shingles Prevention Study Group</creatorcontrib><creatorcontrib>for the Shingles Prevention Study Group</creatorcontrib><title>Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). Methods. A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. Results. The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was <5 years for approximately 80% of recipients. The proportion of vaccinated SPS placebo recipients with prior HZ who developed ≥1 SAE (0.95%) was not significantly different from that of vaccinated SPS placebo recipients with no prior history of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable. Conclusions. These results demonstrate that the general safety of zoster vaccine in older persons is not altered by a recent history of documented HZ, supporting the safety aspect of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendation to administer zoster vaccine to all persons ≥60 years of age with no contraindications, regardless of a prior history of HZ.</description><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - pathology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Health care industry</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - immunology</subject><subject>Herpes zoster vaccine</subject><subject>Herpes Zoster Vaccine - administration & dosage</subject><subject>Herpes Zoster Vaccine - adverse effects</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Major and Brief Reports</subject><subject>Male</subject><subject>Medical practice</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Older adults</subject><subject>Placebos</subject><subject>Preventive medicine</subject><subject>Vaccination</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><subject>VIRUSES</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkTtvFDEUhS1ERJZASQlyEynNJH573CBFeRCkRBSQFDSW14_glXe8sWeI9t9jNMuKVLc43zn36h4APmB0ipGiZ3EILtazVRxxT16BBeZUdkJg-hosECKkw71Sh-BtrSuEEKNCvgGHhApKGRILcPfdBD9uYQ7wZ66jL_DBWBsHD-MAr5LzJW3huZvSWOF1Tik_x-ERXmY7rf0wegdvfNn4ujO_AwfBpOrf7-YRuL---nFx091--_L14vy2s0ySsbOOcxTIUnhhuZAMM-6Md9YRFziyBLsl6xkivUJBUeWQ83aJqeSsMVJaegQ-z7mbabluxnZKMUlvSlybstXZRP1SGeIv_Zh_ayqx6pVoASe7gJKfJl9HvY7V-pTM4PNUNRaMCMJFjxvazagtudbiw34NRvpvBXquQM8VNP7T_7ft6X8_b8DxDjDVmhSKGWyz7zkpcC-JatzHmVvVMZe9zgjvWwqhfwDP1Zxd</recordid><startdate>20130815</startdate><enddate>20130815</enddate><creator>Morrison, Vicki A.</creator><creator>Oxman, Michael N.</creator><creator>Levin, Myron J.</creator><creator>Schmader, Kenneth E.</creator><creator>Guatelli, John C.</creator><creator>Betts, Robert F.</creator><creator>Gelb, Larry D.</creator><creator>Pachucki, Constance T.</creator><creator>Keay, Susan K.</creator><creator>Menzies, Barbara</creator><creator>Griffin, Marie R.</creator><creator>Kauffman, Carol A.</creator><creator>Marques, Adriana R.</creator><creator>Toney, John F.</creator><creator>Simberkoff, Michael S.</creator><creator>Serrao, Richard</creator><creator>Arbeit, Robert D.</creator><creator>Gnann, John W.</creator><creator>Greenberg, Richard N.</creator><creator>Holodniy, Mark</creator><creator>Keitel, Wendy A.</creator><creator>Yeh, Shingshing S.</creator><creator>Davis, Larry E.</creator><creator>Crawford, George E.</creator><creator>Neuzil, Kathy M.</creator><creator>Johnson, Gary R.</creator><creator>Zhang, Jane H.</creator><creator>Harbecke, Rith</creator><creator>Chan, Ivan S. F.</creator><creator>Keller, Paul M.</creator><creator>Williams, Heather M.</creator><creator>Boardman, Kathy D.</creator><creator>Silber, Jeffrey L.</creator><creator>Annunziato, Paula W.</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20130815</creationdate><title>Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster</title><author>Morrison, Vicki A. ; Oxman, Michael N. ; Levin, Myron J. ; Schmader, Kenneth E. ; Guatelli, John C. ; Betts, Robert F. ; Gelb, Larry D. ; Pachucki, Constance T. ; Keay, Susan K. ; Menzies, Barbara ; Griffin, Marie R. ; Kauffman, Carol A. ; Marques, Adriana R. ; Toney, John F. ; Simberkoff, Michael S. ; Serrao, Richard ; Arbeit, Robert D. ; Gnann, John W. ; Greenberg, Richard N. ; Holodniy, Mark ; Keitel, Wendy A. ; Yeh, Shingshing S. ; Davis, Larry E. ; Crawford, George E. ; Neuzil, Kathy M. ; Johnson, Gary R. ; Zhang, Jane H. ; Harbecke, Rith ; Chan, Ivan S. F. ; Keller, Paul M. ; Williams, Heather M. ; Boardman, Kathy D. ; Silber, Jeffrey L. ; Annunziato, Paula W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-cd550f2b6e6c5674145daedcd2df50c21db48402890f939d0decb13754dcd77c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - pathology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Health care industry</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - immunology</topic><topic>Herpes zoster vaccine</topic><topic>Herpes Zoster Vaccine - administration & dosage</topic><topic>Herpes Zoster Vaccine - adverse effects</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Major and Brief Reports</topic><topic>Male</topic><topic>Medical practice</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Older adults</topic><topic>Placebos</topic><topic>Preventive medicine</topic><topic>Vaccination</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><topic>VIRUSES</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morrison, Vicki A.</creatorcontrib><creatorcontrib>Oxman, Michael N.</creatorcontrib><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Schmader, Kenneth E.</creatorcontrib><creatorcontrib>Guatelli, John C.</creatorcontrib><creatorcontrib>Betts, Robert F.</creatorcontrib><creatorcontrib>Gelb, Larry D.</creatorcontrib><creatorcontrib>Pachucki, Constance T.</creatorcontrib><creatorcontrib>Keay, Susan K.</creatorcontrib><creatorcontrib>Menzies, Barbara</creatorcontrib><creatorcontrib>Griffin, Marie R.</creatorcontrib><creatorcontrib>Kauffman, Carol A.</creatorcontrib><creatorcontrib>Marques, Adriana R.</creatorcontrib><creatorcontrib>Toney, John F.</creatorcontrib><creatorcontrib>Simberkoff, Michael S.</creatorcontrib><creatorcontrib>Serrao, Richard</creatorcontrib><creatorcontrib>Arbeit, Robert D.</creatorcontrib><creatorcontrib>Gnann, John W.</creatorcontrib><creatorcontrib>Greenberg, Richard N.</creatorcontrib><creatorcontrib>Holodniy, Mark</creatorcontrib><creatorcontrib>Keitel, Wendy A.</creatorcontrib><creatorcontrib>Yeh, Shingshing S.</creatorcontrib><creatorcontrib>Davis, Larry E.</creatorcontrib><creatorcontrib>Crawford, George E.</creatorcontrib><creatorcontrib>Neuzil, Kathy M.</creatorcontrib><creatorcontrib>Johnson, Gary R.</creatorcontrib><creatorcontrib>Zhang, Jane H.</creatorcontrib><creatorcontrib>Harbecke, Rith</creatorcontrib><creatorcontrib>Chan, Ivan S. F.</creatorcontrib><creatorcontrib>Keller, Paul M.</creatorcontrib><creatorcontrib>Williams, Heather M.</creatorcontrib><creatorcontrib>Boardman, Kathy D.</creatorcontrib><creatorcontrib>Silber, Jeffrey L.</creatorcontrib><creatorcontrib>Annunziato, Paula W.</creatorcontrib><creatorcontrib>Shingles Prevention Study Group</creatorcontrib><creatorcontrib>for the Shingles Prevention Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morrison, Vicki A.</au><au>Oxman, Michael N.</au><au>Levin, Myron J.</au><au>Schmader, Kenneth E.</au><au>Guatelli, John C.</au><au>Betts, Robert F.</au><au>Gelb, Larry D.</au><au>Pachucki, Constance T.</au><au>Keay, Susan K.</au><au>Menzies, Barbara</au><au>Griffin, Marie R.</au><au>Kauffman, Carol A.</au><au>Marques, Adriana R.</au><au>Toney, John F.</au><au>Simberkoff, Michael S.</au><au>Serrao, Richard</au><au>Arbeit, Robert D.</au><au>Gnann, John W.</au><au>Greenberg, Richard N.</au><au>Holodniy, Mark</au><au>Keitel, Wendy A.</au><au>Yeh, Shingshing S.</au><au>Davis, Larry E.</au><au>Crawford, George E.</au><au>Neuzil, Kathy M.</au><au>Johnson, Gary R.</au><au>Zhang, Jane H.</au><au>Harbecke, Rith</au><au>Chan, Ivan S. F.</au><au>Keller, Paul M.</au><au>Williams, Heather M.</au><au>Boardman, Kathy D.</au><au>Silber, Jeffrey L.</au><au>Annunziato, Paula W.</au><aucorp>Shingles Prevention Study Group</aucorp><aucorp>for the Shingles Prevention Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2013-08-15</date><risdate>2013</risdate><volume>208</volume><issue>4</issue><spage>559</spage><epage>563</epage><pages>559-563</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). Methods. A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. Results. The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was <5 years for approximately 80% of recipients. The proportion of vaccinated SPS placebo recipients with prior HZ who developed ≥1 SAE (0.95%) was not significantly different from that of vaccinated SPS placebo recipients with no prior history of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable. Conclusions. These results demonstrate that the general safety of zoster vaccine in older persons is not altered by a recent history of documented HZ, supporting the safety aspect of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendation to administer zoster vaccine to all persons ≥60 years of age with no contraindications, regardless of a prior history of HZ.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>23633406</pmid><doi>10.1093/infdis/jit182</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2013-08, Vol.208 (4), p.559-563 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719896 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Age Aged Aged, 80 and over Applied microbiology Biological and medical sciences Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Fundamental and applied biological sciences. Psychology Health care industry Herpes zoster Herpes Zoster - immunology Herpes zoster vaccine Herpes Zoster Vaccine - administration & dosage Herpes Zoster Vaccine - adverse effects Human viral diseases Humans Infectious diseases Major and Brief Reports Male Medical practice Medical sciences Microbiology Middle Aged Older adults Placebos Preventive medicine Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye VIRUSES |
| title | Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A36%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20Zoster%20Vaccine%20in%20Elderly%20Adults%20Following%20Documented%20Herpes%20Zoster&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Morrison,%20Vicki%20A.&rft.aucorp=Shingles%20Prevention%20Study%20Group&rft.date=2013-08-15&rft.volume=208&rft.issue=4&rft.spage=559&rft.epage=563&rft.pages=559-563&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/jit182&rft_dat=%3Cjstor_pubme%3E42580632%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1642625681&rft_id=info:pmid/23633406&rft_jstor_id=42580632&rfr_iscdi=true |